Clinical Trials Browser

Breast Neoplasms, Influenza, Human

NCT06124131 2025-05-04

BENEFIT-C

Vaccine-Preventable Diseases, COVID-19, Vaccination Hesitancy, Influenza, Human, Patient Acceptance of Health Care, Colorectal Neoplasms, Health Behavior

NCT02860039 2024-10-22

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Phase 2 Completed

170 enrolled 11 charts

Influenza, Human, Neoplasms

NCT03061955 2024-10-04

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

Completed

28 enrolled

Influenza, Human, Neoplasms

NCT03590808 2019-09-19

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

Phase NA Completed

143 enrolled

Influenza, Human

NCT02566265 2019-01-30

SHIVERING 2

Phase 2 Completed

122 enrolled 10 charts

LymphoidPlasma cell

Influenza, Human, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT01205581 2016-09-23

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

Phase 2 Completed

85 enrolled 24 charts

Influenza, Human, Neoplasms

NCT01666782 2016-06-24

IMMUNE

Phase 2 Completed

105 enrolled 10 charts

Influenza, Human, Neoplasms

NCT01031719 2012-09-13

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

Phase 3 Completed

59 enrolled

Influenza, Human, Neoplasms, Virus Diseases

Clinical Trials

VSMART

BENEFIT-C

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

SHIVERING 2

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

IMMUNE

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors